Company Profiles

driven by the PitchBook Platform

Axerion Therapeutics

Description

Developer of disease-modifying therapeutics designed to treat spinal cord injury (SCI), stroke recovery and Alzheimer's disease. The company's Nogo Receptor platform and small molecule oral compounds block the binding of β-amyloid (Aβ) oligomers to PrP in the brain, enabling patients with central nervous system disorders to get proper treatment by stimulating regrowth in axons.

2010

Founded

PRIVATE

Status

1-10

Employees

Conv. Debt

Latest Deal Type

$500k

Latest Deal Amount

$1.66M

Total Amount Raised

Description

Developer of disease-modifying therapeutics designed to treat spinal cord injury (SCI), stroke recovery and Alzheimer's disease. The company's Nogo Receptor platform and small molecule oral compounds block the binding of β-amyloid (Aβ) oligomers to PrP in the brain, enabling patients with central nervous system disorders to get proper treatment by stimulating regrowth in axons.

Website:

www.axeriontherapeutics.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

157 Church Street 19th Floor New Haven, CT 06510United States +1 (203) 208-2384
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Axerion Therapeutics's full profile, request a free trial.

    Axerion Therapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Axerion Therapeutics Investors (2)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Connecticut InnovationsVenture CapitalMinority000 0000000 0000
    State of ConnecticutGovernment000 0000000 0000
    Connecticut Innovations Venture Capital
    State of Connecticut Government

    Axerion Therapeutics Executive Team (7)

    NameTitleBoard
    Seat
    Contact
    Info
    George Maynard Ph.DChief Scientific Officer & President
    Stanley ChoyActing Chief Financial Officer
    Dana Wirak Ph.DDirector
    Sylvia McBrinnCo-Founder & Board Member
    Amanda Hayward Ph.DCo-Founder
    George Maynard Ph.D Chief Scientific Officer & President
    Stanley Choy Acting Chief Financial Officer
    Dana Wirak Ph.D Director
    Sylvia McBrinn Co-Founder & Board Member
    Amanda Hayward Ph.D Co-Founder

    Axerion Therapeutics Board Members (5)

    NameRepresentingRoleSinceContact
    Info
    David ScheerSelfChairman000 0000
    John PuzissSelfBoard Member000 0000
    Lillian MuConnecticut InnovationsSenior Investment Associate000 0000
    Russell TweeddaleConnecticut InnovationsManaging Director, Investments000 0000
    Sylvia McBrinnAxerion TherapeuticsCo-Founder & Board Member000 0000
    David Scheer Chairman Self
    John Puziss Board Member Self
    Lillian Mu Senior Investment Associate Connecticut Innovations
    Russell Tweeddale Managing Director, Investments Connecticut Innovations
    Sylvia McBrinn Co-Founder & Board Member Axerion Therapeutics
    Request full access to PitchBook